About US
Contact us
-
FDA approves Amgen’s sBLA for leukaemia drug BlincytoThe US Food and Drug Administration (FDA) has approved Amgen’s supplemental Biologics License Application (sBLA) for Blincyto (blinatumomab) to include new data that supports the treatment of pediatri2016/9/6
-
Deals this week: Elite Pharmaceuticals, Orexigen Therapeutics, LegoChem BiosciencesElite Pharmaceuticalsand SunGen Pharma LLC have entered a development and licensing agreement for four generic pharmaceutical products. According to the agreement, the two partners will share the cos2016/9/5
-
M&As this week: Sichuan Kelun Pharmaceutical Co. and Avantor Performance MaterialsSichuan Kelun Pharmaceutical Co. has announced plans to acquire the remaining 15% stake in Zhejiang-based pharmaceutical unit for ¥65.3m ($9.78m). "Avantor Performance Materials has announced pla2016/9/5
-
Amgen's plan for a speedy launch of Repatha in India hits the skidsAmgen was aiming to launch its cholesterol-fighter Repatha quickly in India. But a panel of CV and renal specialists blocked the PCSK9 drug instead. The U.S. biotech was aiming toimport and marketRep2016/9/2
-
Boehringer's Pradaxa keeps its antidote edge as FDA swats down Portola contenderLast year, Boehringer Ingelheim’s Pradaxa picked up an edge on its new-age anticoagulant rivals when the FDA approved a reversal agent. Now, the agency has turned back an antidote to blockbuster rival2016/9/2
-
Ex-Insys salespeople plead not guilty in Subsys kickbacks schemeTwo former Insys Therapeutics salespeople indicted in a kickback scheme pleaded not guilty in Manhattan federal court Wednesday. The two are the latest ex-Insys staffers to run afoul of a federal prob2016/9/1
-
J&J braces for biosim attack after losing last-ditch Remicade patent fightJohnson & Johnson lost its court battle to shieldRemicade from encroaching biosimilar competition. A U.S. District Judge on Wednesdaystruck down a key patent on the drug, clearing the way for Cell2016/9/1
-
Boehringer and Saniona to develop new compounds for schizophrenia treatmentGerman company Boehringer Ingelheim and Denmark-based biotech company Saniona have partnered to discover and develop new compounds for the treatment of schizophrenia. After signing the agreement, San2016/8/31
-
UK scientists identify new technique for early diagnosis of Parkinson's diseaseScientists at the University of Edinburgh have identified a new way to detect Parkinson's disease in the early stages of illness. Parkinson’s disease is a progressive brain condition caused by the lo2016/8/31
-
Boehringer Ingelheim, Duke Clinical Research Institute expand collaboration on IPF studyBoehringer Ingelheim Pharmaceuticals and the Duke Clinical Research Institute have expanded their collaboration to create thelargest patient registry for Idiopathic Pulmonary Fibrosis (IPF). IPF is a2016/8/30